A marine-derived meroterpenoid inhibits colorectal cancer via PI3K pathway modulation in mice

Abstract

Colorectal cancer is among the most leading cancers in China, characterized by activating mutations in PIK3CA or aberrant AKT signaling in approximately 30%–40% of cases. Marine natural products, especially those derived from marine fungi, offer a valuable source of novel phosphatidylinositol 3-kinase (PI3K) inhibitors. In this study, two novel phenylspirodrimane-type meroterpenoids, chloropenoids A and B (1 and 2), along with ten known analogues (3–12), were isolated from the marine-derived fungus Stachybotrys chlorohalonatus. The absolute configurations of 1 and 2 were established by time-dependent density functional theory electronic circular dichroism (TDDFT-ECD) calculations. Structural optimization via esterification at the C-2′ position of 3 generated a series of derivatives (3a–3i), among which derivative 3a displayed potent antiproliferative activity against CT-26 colorectal cancer cells. Mechanistic studies revealed that 3a disrupted mitochondrial membrane potential, induced apoptosis (total apoptosis rate: approximately 32% at 12.50 μM), and induced G1-phase cell cycle arrest. Molecular docking and Western blot assays demonstrated that 3a effectively inhibited PI3K phosphorylation, consequently attenuating the PI3K/AKT/mTOR signaling cascade. In vivo evaluation using a BALB/c mouse xenograft model revealed that intraperitoneal administration of 3a (50 mg/kg/day for 10 days) significantly suppressed tumor growth (Tumor Growth Inhibition = 85.2%) compared with the control group, exhibiting superior efficacy and reduced systemic toxicity compared to the standard chemotherapy drug, 5-fluorouracil. These findings identify compound 3a as a promising candidate for further development as a PI3K inhibitor for colorectal cancer therapy and provide critical mechanistic insights into phenylspirodrimane-based antitumor agents.

Keywords

Marine-derived natural product / Fungal meroterpenoid / Structural optimization in drug design / Cytotoxic marine metabolite / Colorectal cancer drug discovery / PI3K inhibitor

References

[1] Bao YR, Feng HL, Yao XS. Stachybotranes A-D, phenylspirodrimanes from the wetland fungus Stachybotrys chartarum with cytotoxic activities. Nat Prod Res. 2022, 36: 3894-3900.

[2] Bruhn T, Schaumlöffel A, Hemberger Y, Bringmann G. Specdis: quantifying the comparison of calculated and experimental electronic circular dichroism spectra. Chirality. 2013, 25: 243-249.

[3] Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW, Knighton DR, Li J, Liu KK, Liu Z, Marx MA, Walls M, Wells PA, Yin MJ, Zhu J, Zientek M. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design. ACS Med Chem Lett. 2012, 4: 91-97.

[4] Cantrell W, Huang Y, Menchaca AA, Kulik G, Welker ME. Synthesis and PI3 kinase inhibition activity of a wortmannin-leucine derivative. Molecules. 2018, 23: 1791.

[5] Chu HW, Sethy B, Hsieh PW, Horng JT. Identification of potential drug targets of broad-spectrum inhibitors with a Michael acceptor moiety using shotgun proteomics. Viruses. 2021, 131756.

[6] Cao F, Liu XM, Wang X, Zhang YH, Yang J, Li W, Luo DQ, Liu YF. Structural diversity and biological activities of indole-diterpenoids from Penicillium janthinellum by co-culture with Paecilomyces formosus. Bioorg Chem. 2023, 141. 106863

[7] Chen M, Hao BC, Zhu XH, Zhang LK, Zheng YY, Zhou XJ, Schäberle TF, Shen L, Wang CY, Liu Y. Molecular networking reveals indole diterpenoids from the marine-derived fungus Penicillium sp. N4–3. Mar Life Sci Technol. 2025, 7302-331.

[8] D'Angelo ND, Kim TS, Andrews K, Booker SK, Caenepeel S, Chen K, D'Amico D, Freeman D, Jiang J, Liu L, McCarter JD, San Miguel T, Mullady EL, Schrag M, Subramanian R, Tang J, Wahl RC, Wang L, Whittington DA, Wu T, Norman MH. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase/mammalian target of rapamycin dual inhibitors. J Med Chem. 2011, 54: 1789-1811.

[9] Davoodi-Moghaddam Z, Jafari-Raddani F, Delshad M, Pourbagheri-Sigaroodi A, Bashash D. Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials. J Cancer Res Clin Oncol. 2023, 149: 15293-15310.

[10] Du HF, Li L, Zhang YH, Wang X, Zhou CY, Zhu HJ, Pittman CU, Shou JW, Cao F. The first dimeric indole-diterpenoids from a marine-derived Penicillium sp. fungus and their potential for anti-obesity drugs. Mar Life Sci Technol. 2025, 7: 120-131.

[11] Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GAet al. . Gaussian 09. 2009, Wallingford, CT, USA, Gaussian Inc.

[12] Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt pathway and glucose metabolism: a dangerous liaison in cancer. Int J Biol Sci. 2024, 20: 3113.

[13] Goldstein MJ, Peters M, Weber BL, Davis CB. Optimizing the therapeutic window of targeted drugs in oncology: potency-guided first-in-human studies. Clin Transl Sci. 2020, 14536-543.

[14] Hernández-Balmaseda I, Guerra IR, Declerck K, Herrera Isidrón JA, Pérez-Novo C, Van Camp G, De Wever O, González K, Labrada M, Carr A, Dantas-Cassali G, Dos Reis DC, Delgado-Roche L, Nuñez RR, Delgado-Hernández R, Fernández MD, Paz-Lopes MT, Vanden Berghe W. Marine seagrass extract of Thalassia testudinum suppresses colorectal tumor growth, motility and angiogenesis by autophagic stress and immunogenic cell death pathways. Mar Drugs. 2021, 19. 52

[15] Han B, Feinstein T, Shi Y, Chen G, Yao Y, Hu C, Shi J, Feng J, Wu H, Cheng Y, Guo QS, Jie Z, Ye F, Zhang Y, Liu Z, Mao W, Zhang L, Lu J, Zhao J, Bazhenova L, Ruiz J, Kloecker GH, Sujith KR, Oliff IA, Wong M, Liu B, Wu Y, Huang L, Sun YDUBLIN-3 study group. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomized controlled trial. Lancet Respir Med. 2024, 12: 775-786.

[16] Han MQ, Zhao YJ, Pang S, Zhu HJ, Luo DQ, Liu YF, Yang K, Cao F. Modulating culture method promotes the production of disulfide-linked resorcylic acid lactone dimers with anti-proliferative activity. Bioorg Chem. 2025, 159. 108418

[17] He LM, Deng X, Ni LH, Cai SQ, Chen J, Liao Z, Zhang M, Shui H, Zhu KK, Wu S, Gao P, Sarotti AM, Hong K, Wu XY, Cai YS. Penicipyrrolidines A-N, pyrrolidine derivatives with inhibitory effects on EMT and fibroblast activation from the mangrove-derived fungus Penicillium sp. DM27. Mar Life Sci Technol. 2025, 7: 313-327.

[18] Jarvis BB, Salemme J, Morals A. Stachybotrys toxins. 1. Natl Toxins. 1995, 3: 10-16.

[19] Kamalov LS, Aripova SF, Isaev MI. Low-molecular-mass metabolites of fungi. III. Stachybotrolide from Stachybotrys alternans. Chem Nat Compd. 1998, 34: 616-619.

[20] Leiphrakpam PD, Are C. PI3K/Akt/mTOR signaling pathway as a target for colorectal cancer treatment. Int J Mol Sci. 2024, 25: 3178.

[21] Li Y, Wu C, Liu D, Proksch P, Guo P, Lin W. Chartarlactams AP, phenylspirodrimanes from the sponge-associated fungus Stachybotrys chartarum with antihyperlipidemic activities. J Nat Prod. 2014, 77138147

[22] Li N, Lu B, Luo C, Cai J, Lu M, Zhang Y, Chen H, Dai M. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America. Cancer Lett. 2021, 522255-268.

[23] Liu D, Li Y, Li X, Cheng Z, Huang J, Proksch P, Lin W. Chartarolides A-C, novel meroterpenoids with antitumor activities. Tetrahedron Lett. 2017, 58: 1826-1829.

[24] Liu L, Graff SL, Wang Y. New emerging therapies targeting PI3K/AKT/mTOR/PTEN pathway in hormonal receptor-positive and HER2-negative breast cancer-current state and molecular pathology perspective. Cancers. 2024, 17. 16

[25] Liu JY, Jiang YY, Li PJ, Yao B, Song YJ, Gao JX, Said G, Gao Y, Lai JY, Shao CL. Discovery of a potential bladder cancer inhibitor CHNQD-01281 by regulating EGFR and promoting infiltration of cytotoxic T cells. Mar Life Sci Technol. 2024, 6: 502-514.

[26] Liu YF, Du HF, Zhang YH, Liu ZQ, Qi XQ, Luo DQ, Cao F. Chaeglobol A, an unusual octocyclic sterol with antifungal activity from the marine-derived fungus Chaetomium globosum HBU-45. Chin Chem Lett. 2025, 36. 109858

[27] Mahalingaiah PK, Palenski T, Van Vleet TR. An in vitro model of hematotoxicity: differentiation of bone marrow-derived stem/progenitor cells into hematopoietic lineages and evaluation of lineage-specific hematotoxicity. Curr Protoc Toxicol. 2018, 76. e45

[28] Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021, 22: 3464.

[29] Mou P, Zhang Q, Peng J, Jiang X, Zhang L, Zhou Z, Zhang C, Zhu Y. Antibacterial phenylspirodrimanes from the marine-derived fungus Stachybotrys sp. SCSIO 40434. Fitoterapia. 2021, 152. 104937

[30] Nazir M, Saleem M, Tousif MI, Anwar MA, Surup F, Ali I, Wang D, Mamadalieva NZ, Alshammari E, Ashour ML, Ashour AM, Ahmed I, Elizbit GIR, Hussain H. Meroterpenoids: a comprehensive update insight on structural diversity and biology. Biomolecules. 2021, 11957.

[31] Noman E, Al-Shaibani MM, Bakhrebah MA, Almoheer R, Al-Sahari M, Al-Gheethi A, Radin Mohamed RMS, Almulaiky YQ, Abdulaal WH. Potential of anti-cancer activity of secondary metabolic products from marine fungi. J Fungi. 2021, 7436.

[32] Nagahawatta DP, Liyanage NM, Jayawardena TU, Jayawardhana HHACK, Jeong SH, Kwon HJ, Jeon YJ. Role of marine natural products in the development of antiviral agents against SARS-CoV-2: potential and prospects. Mar Life Sci Technol. 2024, 6280-297.

[33] Omolekan TO, Chamcheu JC, Buerger C, Huang S. PI3K/AKT/mTOR signaling network in human health and diseases. Cells. 2024, 13: 1500.

[34] Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we making headway?. Front Oncol. 2022, 12. 819128

[35] Qin YD, Fang FM, Zhou JJ, Wang RB, Xu SX, Li LH, Zhang HL. Atranones from Stachybotrys chartarum and their antitumor activities in MG-63 human osteosarcoma cells. Fitoterapia. 2020, 146. 104727

[36] Rateb ME, Ebel R. Secondary metabolites of fungi from marine habitats. Nat Prod Rep. 2011, 28290-344.

[37] Rizvi SMD, Shazi S, Haneef M. A simple click by click protocol to perform docking: autodock 4.2 made easy for non-bioinformaticians. Excli J. 2013, 12: 831-857

[38] Ríos-Hoyo A, Monzonís X, Vidal J, Linares J, Montagut C. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Front Pharmacol. 2024, 15. 1398419

[39] Sun P, Meng LH. Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity. Acta Pharmacol Sin. 2020, 41: 1395-1402.

[40] Sakai K, Watanabe K, Masuda K, Tsuji M, Hasumi K, Endo A. Isolation, characterization and biological activities of novel triprenyl phenols as pancreatic cholesterol esterase inhibitors produced by Stachybotrys sp. F-1839. J Antibiot. 1995, 48: 447-456.

[41] Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304: 554-554.

[42] Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol des. 2010, 24: 417-422.

[43] Smita P, Narayan PA, J K, Gaurav P. Therapeutic drug monitoring for cytotoxic anticancer drugs: principles and evidence-based practices. Front Oncol. 2022, 12. 1015200

[44] Song Y, Mao Q, Zhou M, Liu CJ, Kong L, Hu T. Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2024, 24: 58.

[45] Shaham SH, Vij P, Tripathi MK. Advances in targeted and chemotherapeutic strategies for colorectal cancer: current insights and future directions. Biomedicines. 2025, 13. 642

[46] Ullah A, Ullah S, Waqas M, Khan M, Rehman NU, Khalid A, Jan A, Aziz S, Naeem M, Halim SA, Khan A, Al-Harrasi A. Novel natural inhibitors for glioblastoma by targeting epidermal growth factor receptor and phosphoinositide 3-kinase. Curr Med Chem. 2024, 316596-6613.

[47] Vázquez MJ, Vega A, Rivera-Sagredo A, Jiménez-Alfaro MD, Dı́ez E, Hueso-Rodrı́guez JA. Novel sesquiterpenoids as tyrosine kinase inhibitors produced by Stachybotrys chortarum. Tetrahedron. 2004, 60: 2379-2385.

[48] Voice AT, Tresadern G, Twidale RM, van Vlijmen H, Mulholland AJ. Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations. Chem Sci. 2021, 12: 5511-5516.

[49] Wei J, Gou Z, Wen Y, Luo Q, Huang Z. Marine compounds targeting the PI3K/Akt signaling pathway in cancer therapy. Biomed Pharmacother. 2020, 129. 110484

[50] Wu W, Jing D, Huang X, Yang W, Shao Z. Drp1-mediated mitochondrial fission is involved in oxidized low-density lipoprotein-induced AF cella poptosis. J Orthop Res. 2021, 39: 1496-1504.

[51] Yano H, Nakanishi S, Kimura K, Hanai N, Saitoh Y, Fukui Y, Nonomura Y, Matsuda. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem. 1993, 268: 25846-25856.

[52] Zhao J, Feng J, Tan Z, Liu J, Zhao J, Chen R, Xie K, Zhang D, Li Y, Yu L, Chen X, Dai J. Stachybotrysins A-G, phenylspirodrimane derivatives from the fungus Stachybotrys chartarum. J Nat Prod. 2017, 80: 1819-1826.

[53] Zhang W, Zhu Y, Yu H, Liu X, Jiao B, Lu X. Libertellenone H, a natural pimarane diterpenoid, inhibits thioredoxin system and induces ROS-mediated apoptosis in human pancreatic cancer cells. Molecules. 2021, 26315.

[54] Zhao GG, Tang WL, Zhang JL, Shi PM, Li YZ, Wang J, Shen QQ, Si HX, Jiang LL, Yu X, Zhu HW, Chen GZ, Zhang XX, Jia H. Deep-sea-derived fungi as valuable producers of cytotoxic secondary metabolites and their leads potential. Front Mar Sci. 2022, 9. 929561

RIGHTS & PERMISSIONS

The Author(s)